Publications by authors named "G Pialoux"
We report a case of persistent disseminated mpox evolving over >6 months in an HIV/hepatitis B virus co-infected patient in France who had <200 CD4+ cells/mm, pulmonary and hepatic necrotic lesions, persistent viremia, and nasopharyngeal excretion. Clinical outcome was favorable after 90 days of tecovirimat treatment and administration of human vaccinia immunoglobulins.
View Article and Find Full Text PDFArticle Synopsis
- Mpox, a disease first reported in France in May 2022, led to a recommendation for live Modified Vaccinia Ankara (MVA-BN) vaccination for multiple-partner men who have sex with men (MSM) starting July 11, 2022.
- A study analyzed the changes in sexual behaviors of MSM on HIV pre-exposure prophylaxis (PrEP) and assessed the effects of vaccination on mpox incidence, revealing significant behavioral shifts and a substantial decrease in infection rates post-vaccination.
- The results showed a notable drop in mpox incidence from 67.4 to 24.4 cases per 1000 person-months after the vaccination roll-out, indicating a 99% risk reduction
Article Synopsis
- - The study examined cytomegalovirus (CMV) risk factors in men who have sex with men, focusing on participants in the HIV pre-exposure prophylaxis trial IPERGAY-ANRS.
- - Of the 417 participants, 382 were already CMV positive, showing a high prevalence rate of 91.6%, and 10 new cases were identified during the study.
- - Findings suggest that having many sexual partners increases the likelihood of CMV, with shedding observed in participants who seroconverted.
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design.
Lancet Infect Dis
October 2024
Background: Increased rates of sexually transmitted infections (STIs) are reported among men who have sex with men (MSM) and new interventions are needed. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of chlamydia or syphilis (or both) and whether the meningococcal group B vaccine (4CMenB) could reduce the incidence of gonorrhoea in this population.
Methods: ANRS 174 DOXYVAC is a multicentre, open-label, randomised trial with a 2 × 2 factorial design conducted at ten hospital sites in Paris, France.
Incidence and factors associated with PrEP discontinuation in France.
J Antimicrob Chemother
July 2024
Objectives: HIV pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but some seroconversions occur due to poor adherence or PrEP discontinuation. Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations.
Methods: A retrospective cohort was conducted in three French hospitals between January 2016 and June 2022.